Navigation Links
Researchers develop MRSA-killing paint
Date:8/16/2010

Troy, N.Y. Building on an enzyme found in nature, researchers at Rensselaer Polytechnic Institute have created a nanoscale coating for surgical equipment, hospital walls, and other surfaces which safely eradicates methicillin resistant Staphylococcus aureus (MRSA), the bacteria responsible for antibiotic resistant infections.

"We're building on nature," said Jonathan S. Dordick, the Howard P. Isermann Professor of Chemical and Biological Engineering, and director of Rensselaer's Center for Biotechnology & Interdisciplinary Studies. "Here we have a system where the surface contains an enzyme that is safe to handle, doesn't appear to lead to resistance, doesn't leach into the environment, and doesn't clog up with cell debris. The MRSA bacteria come in contact with the surface, and they're killed."

In tests, 100 percent of MRSA in solution were killed within 20 minutes of contact with a surface painted with latex paint laced with the coating.

The new coating marries carbon nanotubes with lysostaphin, a naturally occurring enzyme used by non-pathogenic strains of Staph bacteria to defend against Staphylococcus aureus, including MRSA. The resulting nanotube-enzyme "conjugate" can be mixed with any number of surface finishes in tests, it was mixed with ordinary latex house paint.

Unlike other antimicrobial coatings, it is toxic only to MRSA, does not rely on antibiotics, and does not leach chemicals into the environment or become clogged over time. It can be washed repeatedly without losing effectiveness and has a dry storage shelf life of up to six months.

The research, led by Dordick and Ravi Kane, a professor in the Department of Chemical and Biological Engineering at Rensselaer, along with collaboration from Dennis W. Metzger at Albany Medical College, and Ravi Pangule, a chemical engineering graduate student on the project, has been published in the July edition of the journal ACS Nano, published by the American Chemical Society.

Dordick said the nanotube-enzyme coating builds on several years of previous work embedding enzymes into polymers. In previous studies, Dordick and Kane discovered that enzymes attached to carbon nanotubes were more stable and more densely packed when embedded into polymers than enzymes alone.

"If we put an enzyme directly in a coating (such as paint) it will slowly pop out," Kane said. "We wanted to create a stabilizing environment, and the nanotubes allow us to do that."

Having established the basics of embedding enzymes into polymers, they turned their attention to practical applications.

"We asked ourselves were there examples in nature where enzymes can be exploited that have activity against bacteria?" Dordick said. The answer was yes and the team quickly focused on lysostaphin, an enzyme secreted by non-pathogenic Staph strains, harmless to humans and other organisms, capable of killing Staphylococcus aureus, including MRSA, and commercially available.

"It's very effective. If you put a tiny amount of lysostaphin in a solution with Staphylococcus aureus, you'll see the bacteria die almost immediately," Kane said.

Lysostaphin works by first attaching itself to the bacterial cell wall and then slicing open the cell wall (the enzyme's name derives from the Greek "lysis" meaning "to loosen or release").

"Lysostaphin is exceptionally selective," Dordick said. "It doesn't work against other bacteria and it is not toxic to human cells."

The enzyme is attached to the carbon nanotube with a short flexible polymer link, which improves its ability to reach the MRSA bacteria, said Kane.

"The more the lysostaphin is able to move around, the more it is able to function." Dordick said.

They successfully tested the resulting nanotube-enzyme conjugate at Albany Medical College, where Metzger maintains strains of MRSA.

"At the end of the day we have a very selective agent that can be used in a wide range of environments paints, coating, medical instruments, door knobs, surgical masks and it's active and it's stable," Kane said. "It's ready to use when you're ready to use it."

The nanotube-enzyme approach is likely to prove superior to previous attempts at antimicrobial agents, which fall into two categories: coatings that release biocides, or coatings that "spear" bacteria.

Coatings that release biocides which work in a manner similar to marine anti-fouling paint pose harmful side-effects and lose effectiveness over time as their active ingredient leaches into the environment.

Coatings that spear bacteria using amphipatic polycations and antimicrobial peptides tend to clog, also losing effectiveness.

The nanotube-lysostaphin coating does neither, said Dordick.

"We spent quite a bit of time demonstrating that the enzyme did not come out of the paint during the antibacterial experiments. Indeed, it was surprising that the enzyme worked as well as it did while remaining embedded near the surface of the paint," Dordick said.

The enzyme's slicing or "lytic" action also means that bacterial cell contents disperse, or can be removed by rinsing or washing the surface.

Kane also said MRSA are unlikely to develop resistance to a naturally occurring enzyme.

"Lysostaphin has evolved over hundreds of millions of years to be very difficult for Staphylococcus aureus to resist," Kane said. "It's an interesting mechanism that these enzymes use that we take advantage of."


'/>"/>

Contact: Mary Martialay
martim12@rpi.edu
518-276-2146
Rensselaer Polytechnic Institute
Source:Eurekalert

Related biology news :

1. Researchers discover genetic link between immune system, Parkinsons disease
2. Ben-Gurion U. researchers receive US-AID MERC grant for water project with the Palestinian authority
3. Illinois researchers use pyrosequencing to study canine intestinal bacteria
4. Researchers find that one type of stem cell creates a niche for another type in bone marrow
5. VIB and UGent researchers identify key mechanisms of cell division in plants
6. Rutgers researchers assess severity of prostate cancers using magnetic resonance imaging
7. Carnegie Mellon researchers turn up brightness on fluorescent probes
8. Researchers demonstrate highly directional terahertz laser rays
9. Hebrew University researchers identify gene related to chronic pain
10. UC Riverside researchers measure diesel emissions on the freeway
11. Windy cities: Researchers invent new tool to calculate hurricane risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Calif. , Dec. 8, 2016  Singulex, Inc., ... Molecule Counting technology, entered into a license and supply ... serving science. The agreement provides Singulex access to Thermo ... Europe is used to diagnose systemic ... United States to aid in assessing the ...
(Date:12/7/2016)...   Veridium , a leader in biometrics-based ... CEO James Stickland . Stickland, a seasoned ... has served in senior executive roles for HSBC, ... expanding a pipeline of venture capital and accelerating ... served as managing director of U.K.-based fintech firm ...
(Date:12/5/2016)... , Dec. 5, 2016  The Office of ... published "Can CT Scans Enhance or Replace Medico ... potential of supporting or replacing forensic autopsies with ... scan. In response to recommendations made ... exploring using CT scans as a potential component ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Eurofins announces the appointment of Sean Murray , National Division ... Mr. Murray will bring valuable expertise to the ... leading international business teams. As the National Division Leader, he will ... status as the global leader in bio-analytical testing services. ... , , ...
(Date:12/8/2016)... Dec. 8, 2016  Anaconda BioMed S.L., a pre-clinical ... the next generation neuro-thrombectomy system for the treatment of ... G. Jovin, MD to join its Scientific Advisory Board ... strategic network of scientific and clinical experts to Anaconda ... the ANCD BRAIN ® to its clinical phase. ...
(Date:12/8/2016)... 8, 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... on developing and commercializing products to treat rare ... announced today the long-term follow-up data from its ... first-in-class Innate Defense Regulator (IDR), in the treatment ... cancer patients undergoing chemoradiation therapy (CRT).  The additional ...
(Date:12/8/2016)... -- Partnering to fuel Philadelphia,s innovative ... Southeastern Pennsylvania (" Ben Franklin "); ... Blue Cross; and Safeguard Scientifics ("Safeguard") (NYSE: ... million funding initiative over a four year period to ... a burgeoning economic vitality in digital health, Ben ...
Breaking Biology Technology: